WO2024095213 - COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS
National phase entry:
Publication Number
WO/2024/095213
Publication Date
10.05.2024
International Application No.
PCT/IB2023/061087
International Filing Date
02.11.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR PREVENTING, AMELIORATING, OR TREATING SICKLE CELL DISEASE AND COMPOSITIONS AND METHODS FOR DISRUPTING GENES AND GENE SEGMENTS
[French]
COMPOSITIONS ET PROCÉDÉS POUR PRÉVENIR, AMÉLIORER OU TRAITER LA DRÉPANOCYTOSE ET COMPOSITION ET PROCÉDÉS POUR PERTURBER DES GÈNES ET DES SEGMENTS DE GÈNES
Applicants **
INCISIVE GENETICS, INC.
THE UNIVERSITY OF BRITISH COLUMBIA
Inventors
LEAVITT, Blair
HILL, Austin
WAGNER, Pamela
CARON, Nicholas
Priority Data
63/381,989
02.11.2022
US
63/517,518
03.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3774 | |
| EPO | Filing, Examination, Granting | 22154 | |
| Japan | Filing, Examination, Granting | 2493 | |
| South Korea | Filing, Examination, Granting | 2788 | |
| USA | Filing, Examination, Granting | 11290 |
Total:
42,499
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides nucleic acids, compositions and vectors containing and their use for effecting gene editing and/or gene expression alteration on sickle cell disease (SCD)-associated genes, e.g., in vivo. The present disclosure further provides compositions for and methods of effecting gene editing and/or gene expression alteration, such as on SCD-associated genes in vivo, and methods of preventing, ameliorating, or treating SCD.[French]
La présente invention concerne des acides nucléiques, des compositions et des vecteurs en contenant et leur utilisation pour effectuer une édition génique et/ou une modification de l'expression génique sur des gènes associés à la drépanocytose (SCD), par exemple, in vivo. La présente invention concerne également des compositions et des procédés permettant d'effectuer une édition génique et/ou une modification de l'expression génique, afin de modifier les gènes associés à la SCD in vivo, ainsi que des procédés de prévention, d'atténuation ou de traitement de la SCD.